All In Biotech

Drug Trial Radar · NCT03365609

A Comparison of Four Different Treatment Regimens of Helicobacter Pylori in Chinese Children

A Comparison of Four Different Treatment Regimens as the First-line Treatment of Helicobacter Pylori in Chinese Children and Investigation of Resistance and Impact factors-a Multicenter Study

Last checked: Nov 19, 2026Latest source record: Feb 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,440 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,440

Planned (sponsor's estimate)

Start

Sep 20, 2017

Primary completion

Oct 1, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
Ying HUANGAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Guangzhou Women and Children's Medical Center; The Children's Hospital of Zhejiang University School of Medicine; Beijing Children's Hospital; Tang-Du Hospital
First posted
Dec 7, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 6 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

With the resistance of Helicobacter pylori increasing, low and unsatisfactory eradication rate (64%) have been observed with standard triple therapy in European children. Which regimen is appropriate for Chinese children? There is no large scale, multi center studies in China about treatment, CYP2C19 gene polymorphism, resistance rate and resistance genotype. Investigators want to perform a research to compare four different treatment regimens(triple therapy, sequential therapy, bismuth quadruple therapy and concomitant therapy)as the first-line treatment of Helicobacter pylori in Chinese children and investigation of resistance, impact factors and changes of microbiota after the therapy. The results of the study will provide theoretical basis to make the new guideline of diagnosis and therapy of Helicobacter pylori in Chinese children. It advance instruct and norm the clinical practice for Chinese pediatrician to increase the cure rate of Helicobacter pylori and decrease the resistance.

Conditions

  • Helicobacter Infections

Interventions

  • triple therapyDrug

    Omeprazole+Amoxicillin+Clarithromycin

  • sequential therapyDrug

    the first 7 days : Omeprazole+Amoxicillin, the last 7 days: Omeprazole+Clarithromycin+Metronidazole

  • bismuth quadruple therapyDrug

    Omeprazole+Amoxicillin+Metronidazole+Colloidal Bismuth Subcitrate

  • concomitant therapyDrug

    Omeprazole+Amoxicillin+Clarithromycin+Metronidazole

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 13C-UBTTime frame: 13C-UBT was assessed at 4-6 weeks after completion of therapy

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Children's hospital of Fudan university

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.